论文部分内容阅读
对马抗毒血清(以下简称 ATS)治疗破伤风的看法不一,有人主张肌肉或静脉注射 ATS,但另有人怀疑其疗效,该制剂可产生过敏反应且半衰期短。目前破伤风病死率仍保留于40%。过去已有鞘内注入 ATS治愈人和动物破伤风的报告,但对晚期破伤风患者则无效。本文报告鞘内注入人破伤风免疫球蛋白(以下简称 TIG)治疗早期破伤风(尚未发生痉挛)的结果。
Different views on the treatment of tetanus by horse antitoxic serum (hereinafter referred to as ATS), some advocated intramuscular or intravenous injection of ATS, but others suspect its efficacy, the preparation can produce anaphylactic reaction and short half-life. The current tetanus mortality remains at 40%. In the past there have been reports of intrathecal ATS in the treatment of human and animal tetanus, but not in patients with advanced tetanus. This article reports the results of an intrathecal injection of human tetanus immunoglobulin (TIG) for the treatment of early tetanus (with no convulsions).